GURUFOCUS.COM » STOCK LIST » Latin America » Brazil » BSP » Biogen Inc (BSP:BIIB34) » Definitions » Deferred Policy Acquisition Costs
Switch to:

Biogen (BSP:BIIB34) Deferred Policy Acquisition Costs

View and export this data going back to 2016. Start your Free Trial

Deferred Policy Acquisition Costs only applies to banks and insurance companies.

Biogen (BSP:BIIB34) Business Description

Biogen logo
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.